KR101279748B1 - 유전자 도입된 수상세포의 제조방법 - Google Patents

유전자 도입된 수상세포의 제조방법 Download PDF

Info

Publication number
KR101279748B1
KR101279748B1 KR1020067010775A KR20067010775A KR101279748B1 KR 101279748 B1 KR101279748 B1 KR 101279748B1 KR 1020067010775 A KR1020067010775 A KR 1020067010775A KR 20067010775 A KR20067010775 A KR 20067010775A KR 101279748 B1 KR101279748 B1 KR 101279748B1
Authority
KR
South Korea
Prior art keywords
cells
dendritic cells
gene
cell
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067010775A
Other languages
English (en)
Korean (ko)
Other versions
KR20060125783A (ko
Inventor
신지 오카노
요시카즈 요네미쯔
가쯔오 스에이시
사토코 시바타
마모루 하세가와
Original Assignee
가부시키가이샤 디나벡크 겐큐쇼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 디나벡크 겐큐쇼 filed Critical 가부시키가이샤 디나벡크 겐큐쇼
Publication of KR20060125783A publication Critical patent/KR20060125783A/ko
Application granted granted Critical
Publication of KR101279748B1 publication Critical patent/KR101279748B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020067010775A 2003-11-04 2004-10-29 유전자 도입된 수상세포의 제조방법 Expired - Fee Related KR101279748B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2003-00374808 2003-11-04
JP2003374808 2003-11-04
JP2004187028 2004-06-24
JPJP-P-2004-00187028 2004-06-24
PCT/JP2004/016089 WO2005042737A1 (ja) 2003-11-04 2004-10-29 遺伝子導入された樹状細胞の製造方法

Publications (2)

Publication Number Publication Date
KR20060125783A KR20060125783A (ko) 2006-12-06
KR101279748B1 true KR101279748B1 (ko) 2013-07-04

Family

ID=34554806

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067010775A Expired - Fee Related KR101279748B1 (ko) 2003-11-04 2004-10-29 유전자 도입된 수상세포의 제조방법

Country Status (8)

Country Link
US (1) US20070269414A1 (enExample)
EP (1) EP1690937B1 (enExample)
JP (2) JPWO2005042737A1 (enExample)
KR (1) KR101279748B1 (enExample)
CN (1) CN1902312B (enExample)
AU (1) AU2004286144A1 (enExample)
CA (1) CA2544786A1 (enExample)
WO (1) WO2005042737A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7335296A (en) 1995-11-01 1997-05-22 Dnavec Research Inc. Recombinant sendai virus
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20020002143A1 (en) * 2000-03-30 2002-01-03 Munehide Kano AIDS virus vaccines using sendai virus vector
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
EP1642966B1 (en) * 2003-06-30 2010-03-03 Dnavec Research Inc. Minus strand rna viral vectors carrying a gene with altered hypermutable regions
AU2004286144A1 (en) * 2003-11-04 2005-05-12 Dnavec Research Inc. Method for producing gene transferred dendritic cells
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
CN101006171A (zh) * 2004-06-24 2007-07-25 株式会社载体研究所 含有单链负链rna病毒的抗癌剂
CA2612168A1 (en) * 2005-06-14 2006-12-21 Dnavec Corporation Methods for producing antibodies
KR20080094910A (ko) * 2006-01-17 2008-10-27 디나벡크 가부시키가이샤 신규 단백질 발현계
EP2143794A1 (en) * 2007-04-27 2010-01-13 Kyushu University, National University Corporation Viral vector for gene therapy
EP2154243B1 (en) * 2007-05-17 2016-01-13 ID Pharma Co., Ltd. Method for production of dendritic cell
AU2008280436A1 (en) * 2007-07-24 2009-01-29 Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre Compositions and methods for generating an immune response in a subject
JP2010537629A (ja) * 2007-08-30 2010-12-09 アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム 動脈形成に関与する経路及びその使用
EP2262889B1 (en) * 2008-03-03 2017-05-03 University Of Toledo Method for the production of dendritic precursor cell line
EP2351599A4 (en) 2008-11-14 2013-05-08 Dnavec Corp METHOD FOR PRODUCING DENDRITIC CELLS
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20220226449A1 (en) * 2019-05-31 2022-07-21 Telethon Kids Institute Immunogenic compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147186A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
JPH01285498A (ja) 1988-05-11 1989-11-16 Mitsubishi Heavy Ind Ltd 宇宙用パネル展開装置
TW232710B (enExample) 1991-09-13 1994-10-21 American Cyanamid Co
JPH05192160A (ja) 1992-01-20 1993-08-03 Banyu Pharmaceut Co Ltd Ｃ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡ及びポリペプチド
JPH07502173A (ja) 1992-10-06 1995-03-09 アクゾ・ノベル・エヌ・ベー 偽性狂犬病ウイルスワクチン
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
EP1314431B1 (en) * 1993-04-30 2008-07-16 Wellstat Biologics Corporation Purified compositions of Newcastle disease virus
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
KR100754091B1 (ko) 1995-10-31 2007-08-31 가부시끼가이샤 디나벡 겡뀨쇼 자율 복제 능력을 갖는 (-)쇄 ｒｎａ 바이러스 벡터
AU7335296A (en) 1995-11-01 1997-05-22 Dnavec Research Inc. Recombinant sendai virus
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
KR100461701B1 (ko) 1996-02-29 2005-04-06 다카라 바이오 가부시키가이샤 바이러스의정제및제거방법
EP0983345A1 (en) * 1997-05-21 2000-03-08 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
DK1186667T3 (da) 1999-05-18 2007-10-22 Dnavec Research Inc Kappegendeficient virusvektor af Paramyxoviridae
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
ATE399206T1 (de) 1999-05-18 2008-07-15 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
US20020123479A1 (en) * 1999-12-08 2002-09-05 Song Elizabeth S. Immunostimulation mediated by gene-modified dendritic cells
US6472208B1 (en) * 1999-12-13 2002-10-29 Héma-Québec Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells
US20020002143A1 (en) * 2000-03-30 2002-01-03 Munehide Kano AIDS virus vaccines using sendai virus vector
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
WO2003004616A2 (en) * 2001-07-05 2003-01-16 Phylogix, Inc. Dendritic cell isolation methods
PT1441591T (pt) * 2001-09-06 2016-10-06 Northwest Biotherapeutics Inc Composições e métodos para ativaçao linfocitária de células dendríticas monocíticas e células para resposta th-1
US20050130123A1 (en) * 2001-09-18 2005-06-16 Makoto Inoue Methods of examining (-) strand rna virus vectors having lowered ability to form grains and method of constructing the same
AU2002327755A1 (en) * 2001-09-28 2003-04-14 Rush-Presbyterian-St. Luke's Medical Center Paramyxoviruses as gene transfer vectors to lung cells
US20040265272A1 (en) * 2001-09-28 2004-12-30 Aikichi Iwamoto Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
US20050191617A1 (en) * 2002-06-03 2005-09-01 Makoto Inoue Pramyxovirusl vectors encoding antibody and utilization thereof
AU2002951082A0 (en) * 2002-08-30 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic cellular agents
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
AU2003296439B2 (en) * 2002-12-10 2009-05-07 Argos Therapeutics, Inc. In situ maturation of dendritic cells
AU2004286144A1 (en) * 2003-11-04 2005-05-12 Dnavec Research Inc. Method for producing gene transferred dendritic cells
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
CA2553976C (en) * 2004-01-22 2013-09-24 Dnavec Research Inc. Method for producing minus-strand rna viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken .beta.-actin promoter
US20080199438A1 (en) * 2004-03-16 2008-08-21 Dnavec Research Inc. Methods For Suppressing Tumor Proliferation
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
CN101006171A (zh) * 2004-06-24 2007-07-25 株式会社载体研究所 含有单链负链rna病毒的抗癌剂
KR20080031167A (ko) * 2005-04-20 2008-04-08 디나벡크 가부시키가이샤 알츠하이머병 치료용의 고도로 안전한 비강투여용 유전자백신
KR20090027693A (ko) * 2006-05-31 2009-03-17 디나벡크 가부시키가이샤 알츠하이머병 치료제
EP2154243B1 (en) * 2007-05-17 2016-01-13 ID Pharma Co., Ltd. Method for production of dendritic cell

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CH Jin 등. Gene Therapy. 2003.02. Vol. 10, No. 3, 272-277. *
CH Jin 등. Gene Therapy. 2003.02. Vol. 10, No. 3, 272-277.*
Hidetoshi Sumimoto 등. Journal of Immunological Methods. 2002. Vol. 271, Issues 1-2, 페이지 153-165. *
Hidetoshi Sumimoto 등. Journal of Immunological Methods. 2002. Vol. 271, Issues 1-2, 페이지 153-165.*

Also Published As

Publication number Publication date
EP1690937A4 (en) 2007-01-03
KR20060125783A (ko) 2006-12-06
WO2005042737A1 (ja) 2005-05-12
JP2012065652A (ja) 2012-04-05
AU2004286144A1 (en) 2005-05-12
AU2004286144A2 (en) 2005-05-12
US20070269414A1 (en) 2007-11-22
CN1902312B (zh) 2011-02-23
HK1103418A1 (en) 2007-12-21
CN1902312A (zh) 2007-01-24
EP1690937B1 (en) 2012-10-17
EP1690937A1 (en) 2006-08-16
JPWO2005042737A1 (ja) 2007-05-10
CA2544786A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
KR101279748B1 (ko) 유전자 도입된 수상세포의 제조방법
KR101270839B1 (ko) Ｒｎａ 바이러스가 도입된 수상세포를 포함하는 항암제
EP1561819A1 (en) Method of transferring gene into t cells
US7521043B2 (en) Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
EP2143794A1 (en) Viral vector for gene therapy
HK1089208A (en) Method of constructing transgenic dendritic cell
HK1103418B (en) Method for producing gene transferred dendritic cells
HK1106793A (en) Anticancer agent containing minus-strand rna virus
HK1078108A (en) Method of transferring gene into t cells
HK1094874A (en) Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines
HK1106794B (en) Anticancer agent containing dendritic cell having rna virus transferred thereinto

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160622

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160622